ExoCoBio completed the acquisition of BENEV.

ExoCoBio, a provider of exosome-based regenerative aesthetics, completed the acquisition of BENEV, a global medical aesthetic company based in the US. Financial terms were not disclosed. "We are truly grateful and pleased to announce ExoCoBio's acquisition of BENEV. We have been on a journey together as a strategic and financial partner for the last six years since the US launch of Exosome Regenerative Complex. With this acquisition, we are confident that our expertise, standing in the industry and brand, paired with ExoCoBio's science, technology, funding and pipeline products will generate a strong synergy for our strategic growth in the global medical aesthetic market," Ethan Min, BENEV CEO.